Biocon has informed that it enclosed the press release titled ‘Biocon’s Pertuzumab Gets Marketing Authorization in EU, First Biosimilar Approved Under New Tailored Clinical Approach’. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.